Prognose

Das durchschnittliche Kursziel der Analysten beträgt +2,88€(+33,95%). Der Median liegt bei +2,76€(+28,37%).

Kaufen	4
Halten	8
Verkaufen	2

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	7 / 18
Levermann-Strategie	-4 / 13

News

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK , March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will be prominently featured at Digestive Disease Week (DDW) 2025, the world's premier meeting for gastroenterologists and other digestive disease professionals, to be held in May.» Mehr auf prnewswire.com
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concierge medicine contracts Secured first agreement to pay for EsoGuard under state biomarker legislation Conference call and webcast to be held today, March 24 th at 8:30 AM EDT NEW YORK , March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast The webcast will take place on Monday, March 24, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.» Mehr auf prnewswire.com
Think It's Too Late to Buy Lucid Group? Here's the Biggest Reason Why There's Still Time.
Typically, stocks expected to grow sales significantly in the year to come are priced at a premium. And to be sure, Lucid Group (LCID 5.92%) shares aren't necessarily cheap at 7.3 times sales.» Mehr auf fool.com

Unternehmenszahlen

Im letzten Quartal hatte Lucid 'A' einen Umsatz von 225,33 Mio€ und ein Nettoeinkommen von −381,73 Mio€

(EUR)	Dez. 2024	YOY
Umsatz	+225,33 Mio	58,51%
Bruttoeinkommen	−200,64 Mio	12,29%
Nettoeinkommen	−381,73 Mio	35,45%
EBITDA	−283,99 Mio	45,73%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+6,74 Mrd€
Anzahl Aktien	3,03 Mrd
52 Wochen-Hoch/Tief	+4,07€ - +1,77€
Dividenden	Nein
Beta	0,98
KGV (PE Ratio)	−2,18
KGWV (PEG Ratio)	−0,02
KBV (PB Ratio)	+1,53
KUV (PS Ratio)	+9,08

Unternehmensprofil

Die Lucid Group, Inc. ist ein Technologie- und Automobilunternehmen, das Technologien für Elektrofahrzeuge (EV) entwickelt. Das Unternehmen entwirft, konstruiert und baut Elektrofahrzeuge, EV-Antriebsstränge und Batteriesysteme. Zum 31. Dezember 2021 betrieb das Unternehmen zwanzig Einzelhandelsstudios in den Vereinigten Staaten. Die Lucid Group, Inc. wurde 2007 gegründet und hat ihren Hauptsitz in Newark, Kalifornien.